US 12,465,619 B2
Use of polar lipids to treat or prevent gestational diabetes mellitus
Sophie Yvette Fabienne Christine Gallier, Auckland (NZ); Angela Marie Rowan, Auckland (NZ); and Philip Newton Baker, Auckland (NZ)
Assigned to FONTERRA CO-OPERATIVE GROUP LIMITED, Auckland (NZ)
Appl. No. 17/253,081
Filed by FONTERRA CO-OPERATIVE GROUP LIMITED, Auckland (NZ)
PCT Filed Jun. 24, 2019, PCT No. PCT/IB2019/055285
§ 371(c)(1), (2) Date Dec. 16, 2020,
PCT Pub. No. WO2019/244137, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 743704 (NZ), filed on Jun. 22, 2018.
Prior Publication US 2021/0113623 A1, Apr. 22, 2021
Int. Cl. A61K 35/20 (2006.01); A23C 9/123 (2006.01); A23C 9/142 (2006.01); A23C 9/152 (2006.01); A23L 33/00 (2016.01); A23L 33/115 (2016.01); A23L 33/135 (2016.01); A61K 35/747 (2015.01)
CPC A61K 35/20 (2013.01) [A23C 9/1232 (2013.01); A23C 9/142 (2013.01); A23C 9/1528 (2013.01); A23L 33/115 (2016.08); A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61K 35/747 (2013.01)] 14 Claims
 
1. A method of reducing the risk of gestational diabetes mellitus (GDM) in a pregnant subject in need thereof comprising:
administering daily at least 0.2 g of polar lipids derived from non-human mammalian milk for a minimum period of from 14 weeks to 22 weeks gestation, wherein the polar lipids comprise one or more phospholipids and one or more gangliosides.